- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Yale Physicians Building800 Howard AvenueNew Haven, CT 06519
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- VA Connecticut Healthcare950 Campbell AvenueWest Haven, CT 06516
Fed Ghali, MD
Biography
Fed Ghali, MD, is a urologic oncologist who specializes in treating cancers of the bladder, ureter, kidney, and testis.
Dr. Ghali became interested in the specialty of urology early in his first year of medical school. “I watched a urologic surgeon build a bladder out of intestine and I was blown away,” he says. “I knew I found the right field where I could do challenging surgery, make a meaningful impact on people’s lives, and still do research that I love.”
When it comes to working with patients, Dr. Ghali says he keeps in mind the unique experience each patient is having with their illness. “This is important, even as we treat and learn from many patients with similar diseases,” he says. “Having the benefits of being a high-volume cancer center while recognizing the individual struggle of each patient is key to high quality and compassionate care. Each patient is more than a statistic.”
Dr. Ghali says he also recognizes that the patient in front of him in his office “is often consumed by this new and devastating thing we are trying to treat. I strive to be compassionate and conscious of what they are feeling. I share all the pertinent information I have with patients and avoid sugarcoating or withholding data. Patients are more comfortable when they feel they have power, are in control, and not alone.”
An active researcher, Dr. Ghali’s interests include clinical trial design and biomarker development, which is identifying molecules that signal what is going on with a disease in a patient’s body.
“New biomarkers are urgently needed in bladder cancer, not just to signal the presence of cancer, but to help us monitor response to therapy, and ultimately guide patients into more individualized treatment options” he says. “At Yale, we are working hard to bring cutting edge clinical trials and scientific discoveries to patients with urologic cancers.”
Titles
- Assistant Professor
Education & Training
- Society of Urologic Oncology - FellowUniversity of Washington (2023)
- Urology ResidentUniversity of California, San Diego (2021)
- InternshipUniversity of California, San Diego (2017)
- MDGeisel School of Medicine, at Dartmouth, Medicine (2016)
- BSCal Poly San Luis Obispo, Microbiology (2011)
Additional Information
- AB of Urology, Urology (2025)
- James S, Kandala K, Ghali F. Validation of an integrated statistical framework for reconstructing individual-patient data from time-to-event curves. Journal Of Clinical Oncology 2026, 44: e23432-e23432. DOI: 10.1200/jco.2026.44.16_suppl.e23432.
- Rahman S, Keervani K, Zhao X, Perry C, Mu P, Martin D, Tan W, Hesse D, Petrylak D, Warrick J, Kumar D, Humphrey P, Ghali F. Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis. Frontiers In Oncology 2026, 16: 1807817. PMID: 42200013, PMCID: PMC13199070, DOI: 10.3389/fonc.2026.1807817.
- Ward B, Bevilacqua M, Tan W, Hesse D, Ghali F. IP02-08 EFFICACY OF NADOFARAGENE FIRADENOVEC IN DOUBLY RESISTANT PATIENTS: A REAL WORLD CASE SERIES. Journal Of Urology 2026, 215: e63. DOI: 10.1097/01.ju.0001191276.85430.b0.08.
- Rahman S, Xi A, Jalfon M, Petrylak D, Ghali F. PD15-13 EVALUATING THE EFFECT OF PRIOR CHECKPOINT INHIBITOR EXPOSURE ON OUTCOMES WITH ENFORTUMAB VEDOTIN AND PEMBROLIZUMAB IN FIRST LINE METASTATIC BLADDER CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2026, 215: e868. DOI: 10.1097/01.ju.0001191528.11208.bf.13.
- Ghali F, Kandala K, Rahman S, Jalfon M, Perry C, James S. IP41-19 SIMULATING THE IMPACT OF ADJUVANT IMMUNOTHERAPY IN THE NIAGARA TRIAL USING GATED COUNTERFACTUAL SURVIVAL MODELING. Journal Of Urology 2026, 215: e843. DOI: 10.1097/01.ju.0001191520.88130.94.19.
- Jalfon M, Rahman S, Hesse D, Ghali F. IP41-21 EVALUATING EFFECT OF PRIOR CHECKPOINT INHIBITOR EXPOSURE ON DISEASE CONTROL WITH ENFORTUMAB VEDOTIN + PEMBROLIZUMAB IN FIRST LINE METASTATIC BLADDER CANCER. Journal Of Urology 2026, 215: e844. DOI: 10.1097/01.ju.0001191520.88130.94.21.
- Palencia P, Sivanesan N, Rahman S, Ghali F, Hesse D, Colberg J, Sridhar A, Kelly J, Lee B, Kamat A, Tan W. Partial Cystectomy for Muscle-Invasive Bladder Cancer. Cancers 2025, 17: 2562. PMID: 40805257, PMCID: PMC12346575, DOI: 10.3390/cancers17152562.
- Rahman S, Martin D, Keervani K, James S, Humphrey P, Hesse D, Tan W, Patel S, Wright J, Ghali F. Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer. Cancers 2025, 17: 2536. PMID: 40805235, PMCID: PMC12346734, DOI: 10.3390/cancers17152536.
- Smani S, Lokeshwar S, Jalfon M, Heckscher D, Press B, Heacock D, Leapman M, Kenney P, Ghali F. Development and Utilization of a Novel Electronic Health Record–Based Care Pathway for Nonmuscle-Invasive Bladder Cancer. Urology Practice 2025, 12: 628-631. PMID: 40637707, DOI: 10.1097/upj.0000000000000872.
- James S, Rahman S, Ghali F. MP14-05 MODELING SURVIVAL OUTCOMES OF KEYNOTE-564 WITH STANDARD OF CARE CONTROL ARM TREATMENT: A SIMULATION STUDY. Journal Of Urology 2025, 213: e486. DOI: 10.1097/01.ju.0001109872.73672.99.05.
- Smani S, DuBois J, Zhao K, Sutherland R, Rahman S, Humphrey P, Hesse D, Tan W, Martin D, Lokeshwar S, Ghali F. Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer. Current Oncology Reports 2025, 27: 236-246. PMID: 39976835, DOI: 10.1007/s11912-025-01645-7.
- Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.
- Bakaloudi D, Koehne E, Diamantopoulos L, Holt S, Sekar R, Ghali F, Vakar-Lopez F, Nyame Y, Psutka S, Gore J, de la Calle C, Lin D, Schade G, Liao J, Hsieh A, Yezefski T, Hawley J, Yu E, Montgomery R, Grivas P, Wright J. Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study. Clinical Genitourinary Cancer 2024, 22: 102208. PMID: 39265260, DOI: 10.1016/j.clgc.2024.102208.
- Ghali F, Holt S, Koehne E, Chen J, Weg E, Liao J, Zeng J, Grivas P, Hawley J, Hsieh A, Montgomery R, Wright J. Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older. Frontiers In Oncology 2024, 14: 1341655. PMID: 38812783, PMCID: PMC11133586, DOI: 10.3389/fonc.2024.1341655.
- Koehne E, Bakaloudi D, Ghali F, Nyame Y, Schade G, Grivas P, Yezefski T, Hawley J, Yu E, Hsieh A, Montgomery R, Psutka S, Gore J, Wright J. Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102100. PMID: 38763862, DOI: 10.1016/j.clgc.2024.102100.
- Rahman S, Ryan S, Kim J, Kenney P, Ghali F. Clinical Trials and Climate Change: Doing Our Part While Pursuing Progress. European Urology Focus 2023, 9: 861-862. PMID: 38042649, DOI: 10.1016/j.euf.2023.11.011.
- Ghali F, Vakar-Lopez F, Roudier M, Garcia J, Arora S, Cheng H, Schweizer M, Haffner M, Lee J, Yu E, Grivas P, Montgomery B, Hsieh A, Wright J, Lam H. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. Clinical Genitourinary Cancer 2023, 21: 669-678. PMID: 37344281, PMCID: PMC10674028, DOI: 10.1016/j.clgc.2023.05.014.
- Ghali F, Wright J, Grivas P. The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities. European Urology Oncology 2023, 6: 321-322. PMID: 37045706, DOI: 10.1016/j.euo.2023.03.006.
- Ghali F, Zhao Y, Patel D, Jewell T, Yu E, Grivas P, Montgomery R, Gore J, Etzioni R, Wright J. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis. European Urology Open Science 2022, 47: 58-64. PMID: 36601043, PMCID: PMC9806712, DOI: 10.1016/j.euros.2022.11.003.
- Raheem A, Landi I, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, De Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Santok G, Tadifa J, Syling J, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Bazan A, Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Ghaith A, Hagras A, Ghoneem A, Eissa A, Alqahtani A, Rumaih A, Alwahabi A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study. International Journal Of Urology 2022, 30: 308-317. PMID: 36478459, DOI: 10.1111/iju.15108.
- Miron B, Hawley J, Geynisman D, Mouw K, Sfakianos J, Weg E, Ghali F, Wright J, Grivas P, Khaki A. Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer. Advances In Oncology 2022, 2: 213-225. DOI: 10.1016/j.yao.2022.02.007.
- Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Roussel E, Pavan N, Antonelli A, Zhang S, Ghali F, Patel D, Javier-Desloges J, Bradshaw A, Rubio J, Guruli G, Tracey A, Campi R, Albersen M, Furlan M, McKay RR, Derweesh IH. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer 2022, 20: 326-333. PMID: 35585014, DOI: 10.1016/j.clgc.2022.03.013.
- Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.
- Javier-DesLoges J, Meagher M, Soliman S, Yuan J, Hakimi K, Ghali F, Nalawade V, Patel DN, Monga M, Murphy JD, Derweesh I. Disparities in Telemedicine Utilization for Urology Patients During the COVID-19 Pandemic. Urology 2022, 163: 76-80. PMID: 34979219, PMCID: PMC8719918, DOI: 10.1016/j.urology.2021.11.037.
- Javier-DesLoges JF, Meagher MF, Walia A, Nguyen MV, Perry JM, Narasimhan RS, Hakimi K, Soliman S, Yuan J, Chakoumakos MA, Ghali F, Patel DN, Wan F, Murphy JD, Derweesh IH. Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients. Urologic Oncology Seminars And Original Investigations 2021, 39: 837.e1-837.e7. PMID: 34580026, DOI: 10.1016/j.urolonc.2021.08.021.
- Ghali F, Kane C. Re: Association of Black Race with Prostate Cancer–specific and Other-cause Mortality. European Urology 2021, 80: 758-759. PMID: 34535345, DOI: 10.1016/j.eururo.2021.09.004.
- Abdel Raheem A, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, DE Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Tadifa J, Santok G, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Aguilera Bazan A, Ballesteros Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Alwahabi A, Alqahtani A, Rumaih A, Ghaith A, Ghoneem A, Hagras A, Eissa A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. Warm ischemia time length during on-clamp partial nephrectomy: dose it really matter? Minerva Urologica E Nefrologica 2021, 74: 194-202. PMID: 34308610, DOI: 10.23736/s2724-6051.21.04466-9.
- Javier-DesLoges JF, Yuan J, Soliman S, Hakimi K, Meagher MF, Ghali F, Hsiang W, Patel DN, Kim SP, Murphy JD, Parsons JK, Derweesh IH. Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act. JAMA Network Open 2021, 4: e2116267. PMID: 34269808, PMCID: PMC8285737, DOI: 10.1001/jamanetworkopen.2021.16267.
- Wu Z, Chen Q, Djaladat H, Minervini A, Uzzo R, Sundaram C, Rha K, Gonzalgo M, Mehrazin R, Mazzone E, Marcus J, Danno A, Porter J, Asghar A, Ghali F, Guruli G, Douglawi A, Cacciamani G, Ghoreifi A, Simone G, Margulis V, Ferro M, Tellini R, Mari A, Srivastava A, Steward J, Al-Qathani A, Al-Mujalhem A, Bhattu A, Mottrie A, Abdollah F, Eun D, Derweesh I, Veccia A, Autorino R, Wang L. A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group). European Urology Focus 2021, 8: 173-181. PMID: 33549537, DOI: 10.1016/j.euf.2021.01.014.
- Patel DN, Ghali F, Meagher MF, Javier-Desloges J, Patel SH, Soliman S, Hakimi K, Yuan J, Murphy J, Derweesh IH. Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database. Urologic Oncology Seminars And Original Investigations 2020, 39: 79.e1-79.e8. PMID: 33160847, DOI: 10.1016/j.urolonc.2020.10.015.
- Ghali F, Daly W, Hansen M, Hayn M, Sammon J, Beaule L, Sarkar R, Murphy J, Kader A, Derweesh I, Rose B, Ryan S. Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy. Urologic Oncology Seminars And Original Investigations 2020, 39: 130.e1-130.e7. PMID: 33121914, DOI: 10.1016/j.urolonc.2020.08.035.
- Ryan S, Patel D, Ghali F, Patel S, Sarkar R, Yim K, Eldefrawy A, Cotta B, Bradshaw A, Meagher M, Hamilton Z, Murphy J, Derweesh I. Impact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database. Minerva Urologica E Nefrologica 2020, 73: 233-244. PMID: 32748614, DOI: 10.23736/s2724-6051.20.03728-5.
- Meagher M, Lane B, Capitanio U, Mehrazin R, Bradshaw A, Noyes S, Larcher A, Eldefrawy A, Ghali F, Patel D, Bruinius J, Dutt R, Keiner C, Miller N, Wan F, Montorsi F, Derweesh I. Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma. World Journal Of Urology 2020, 39: 1195-1201. PMID: 32556559, DOI: 10.1007/s00345-020-03299-5.
- Roussel E, Campi R, Larcher A, Verbiest A, Antonelli A, Palumbo C, Derweesh I, Ghali F, Bradshaw A, Meagher M, Heck M, Amiel T, Kriegmair M, Rubio J, Musquera M, D’Anna M, Autorino R, Guruli G, Veccia A, Linares-Espinos E, Van Bruwaene S, Hevia V, Porpiglia F, Checcucci E, Minervini A, Mari A, Pavan N, Claps F, Marchioni M, Capitanio U, Beuselinck B, Mir M, Albersen M, Group O. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. European Urology Oncology 2020, 3: 523-529. PMID: 32414697, DOI: 10.1016/j.euo.2020.04.006.
- Patel S, Uzzo R, Larcher A, Peyronnet B, Lane B, Pruthi D, Reddy M, Capitanio U, Joshi S, Noyes S, Eldefrawy A, Ghali F, Meagher M, Hamilton Z, Yim K, Nasseri R, Bradshaw A, Dey S, Kirmiz S, Wan F, Liss M, Bensalah K, Montorsi F, Derweesh I. Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical Genitourinary Cancer 2020, 18: e723-e729. PMID: 32600941, DOI: 10.1016/j.clgc.2020.05.002.
- Greear G, Ghali F, Hsieh T. Semirigid penile prosthesis: technique and review of literature. Journal Of Visualized Surgery 2020, 6: 17-17. DOI: 10.21037/jovs.2019.11.07.
- Greear G, Ghali F, Hsieh T. Semirigid penile prosthesis. ASVIDE 2020, 7: 37-37. DOI: 10.21037/asvide.2020.037.
- Hamilton Z, Capitanio U, Pruthi D, Ghali F, Larcher A, Patel D, Eldefrawy A, Patel S, Cotta B, Bradshaw A, Meagher M, Miller N, Carenzi C, Wan F, Liss M, McGregor T, Montorsi F, Derweesh I. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria. Urology 2019, 138: 60-68. PMID: 31836465, DOI: 10.1016/j.urology.2019.11.036.
- Ghali F, Elbakry A, Hamilton Z, Yim K, Nasseri R, Patel S, Eldefrawy A, Ryan S, Bradshaw A, Meagher M, Bree K, Reddy M, Lee H, Derweesh I. Robotic partial nephrectomy for clinical T2a renal mass is associated with improved trifecta outcome compared to open partial nephrectomy: a single surgeon comparative analysis. World Journal Of Urology 2019, 38: 1113-1122. PMID: 31701211, DOI: 10.1007/s00345-019-02994-2.
- Roberts J, Ghali F, Aganovic L, Bechis S, Healy K, Rivera-Sanfeliz G, Autorino R, Derweesh I. Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiology. Abdominal Radiology 2019, 44: 3893-3905. PMID: 31701194, DOI: 10.1007/s00261-019-02293-9.
- Ghali F, Patel S, Derweesh I. Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma. Journal Of Oncology 2019, 2019: 7309205. PMID: 31057615, PMCID: PMC6463563, DOI: 10.1155/2019/7309205.
- Shee K, Koo K, Wu X, Ghali F, Halter R, Hyams E. A novel ex vivo trainer for robotic vesicourethral anastomosis. Journal Of Robotic Surgery 2019, 14: 21-27. PMID: 30689167, DOI: 10.1007/s11701-019-00926-1.
- Ghali F, Dagrosa L, Moses R, Ursiny M, Eisner B, Pais V. Changing incidence of factitious renal stone disease. Clinical Nephrology 2018, 90: 102-105. PMID: 29882511, DOI: 10.5414/cn109331.
- Raheem O, Ghali F, Rajasekaran M. Chapter 26 Penile Fibrogenesis Affecting Men’s Reproductive and Sexual Health Role of Age and Environmental Factors. 2018, 423-437. DOI: 10.1016/b978-0-12-801299-4.00026-8.
- Shee K, Ghali F, Hyams E. Practice Makes Perfect: Correlations Between Prior Experience in High-level Athletics and Robotic Surgical Performance Do Not Persist After Task Repetition. Journal Of Surgical Education 2017, 74: 630-637. PMID: 28087244, DOI: 10.1016/j.jsurg.2016.12.008.
- Ghali F, Celaya M, Laviolette M, Ingimarsson J, Carlos H, Rees J, Hyams E. Does Travel Time to a Radiation Facility Impact Patient Decision‐Making Regarding Treatment for Prostate Cancer? A Study of the New Hampshire State Cancer Registry. The Journal Of Rural Health 2016, 34: s84-s90. PMID: 27862285, DOI: 10.1111/jrh.12224.
- Ghali F, Moses R, Raffin E, Hyams E. What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution’s experience. Scandinavian Journal Of Urology 2016, 50: 370-373. PMID: 27438524, DOI: 10.1080/21681805.2016.1201856.
- Dagrosa L, Ghali F, Gormley E. Renal Papillary Necrosis Appearing as Bladder Cancer on Imaging. Journal Of Endourology Case Reports 2016, 2: 27-29. PMID: 27579408, PMCID: PMC4996587, DOI: 10.1089/cren.2016.0011.
- Ghali F, Pattison E, Pais V. Keratinized squamous metaplasia of the upper urinary tract resulting in recurrent renal colic. Clinical Nephrology 2015, 84: 251-3. PMID: 26249552, DOI: 10.5414/cn108581.
- Moses R, Ghali F, Pais V, Hyams E. Unplanned Hospital Return for Infection following Ureteroscopy—Can We Identify Modifiable Risk Factors? Journal Of Urology 2015, 195: 931-936. PMID: 26410731, DOI: 10.1016/j.juro.2015.09.074.
- Ghali F, Hyams E. Heterotopic Pancreatic Tail Appearing as Adrenal Mass in a Patient With Left Pelvic Kidney. Urology 2015, 85: e37-e38. PMID: 25917743, DOI: 10.1016/j.urology.2015.01.037.
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Yale Physicians Building800 Howard AvenueNew Haven, CT 06519
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- VA Connecticut Healthcare950 Campbell AvenueWest Haven, CT 06516
Biography
Fed Ghali, MD, is a urologic oncologist who specializes in treating cancers of the bladder, ureter, kidney, and testis.
Dr. Ghali became interested in the specialty of urology early in his first year of medical school. “I watched a urologic surgeon build a bladder out of intestine and I was blown away,” he says. “I knew I found the right field where I could do challenging surgery, make a meaningful impact on people’s lives, and still do research that I love.”
When it comes to working with patients, Dr. Ghali says he keeps in mind the unique experience each patient is having with their illness. “This is important, even as we treat and learn from many patients with similar diseases,” he says. “Having the benefits of being a high-volume cancer center while recognizing the individual struggle of each patient is key to high quality and compassionate care. Each patient is more than a statistic.”
Dr. Ghali says he also recognizes that the patient in front of him in his office “is often consumed by this new and devastating thing we are trying to treat. I strive to be compassionate and conscious of what they are feeling. I share all the pertinent information I have with patients and avoid sugarcoating or withholding data. Patients are more comfortable when they feel they have power, are in control, and not alone.”
An active researcher, Dr. Ghali’s interests include clinical trial design and biomarker development, which is identifying molecules that signal what is going on with a disease in a patient’s body.
“New biomarkers are urgently needed in bladder cancer, not just to signal the presence of cancer, but to help us monitor response to therapy, and ultimately guide patients into more individualized treatment options” he says. “At Yale, we are working hard to bring cutting edge clinical trials and scientific discoveries to patients with urologic cancers.”
Titles
- Assistant Professor
Education & Training
- Society of Urologic Oncology - FellowUniversity of Washington (2023)
- Urology ResidentUniversity of California, San Diego (2021)
- InternshipUniversity of California, San Diego (2017)
- MDGeisel School of Medicine, at Dartmouth, Medicine (2016)
- BSCal Poly San Luis Obispo, Microbiology (2011)
Additional Information
- AB of Urology, Urology (2025)
- James S, Kandala K, Ghali F. Validation of an integrated statistical framework for reconstructing individual-patient data from time-to-event curves. Journal Of Clinical Oncology 2026, 44: e23432-e23432. DOI: 10.1200/jco.2026.44.16_suppl.e23432.
- Rahman S, Keervani K, Zhao X, Perry C, Mu P, Martin D, Tan W, Hesse D, Petrylak D, Warrick J, Kumar D, Humphrey P, Ghali F. Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis. Frontiers In Oncology 2026, 16: 1807817. PMID: 42200013, PMCID: PMC13199070, DOI: 10.3389/fonc.2026.1807817.
- Ward B, Bevilacqua M, Tan W, Hesse D, Ghali F. IP02-08 EFFICACY OF NADOFARAGENE FIRADENOVEC IN DOUBLY RESISTANT PATIENTS: A REAL WORLD CASE SERIES. Journal Of Urology 2026, 215: e63. DOI: 10.1097/01.ju.0001191276.85430.b0.08.
- Rahman S, Xi A, Jalfon M, Petrylak D, Ghali F. PD15-13 EVALUATING THE EFFECT OF PRIOR CHECKPOINT INHIBITOR EXPOSURE ON OUTCOMES WITH ENFORTUMAB VEDOTIN AND PEMBROLIZUMAB IN FIRST LINE METASTATIC BLADDER CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2026, 215: e868. DOI: 10.1097/01.ju.0001191528.11208.bf.13.
- Ghali F, Kandala K, Rahman S, Jalfon M, Perry C, James S. IP41-19 SIMULATING THE IMPACT OF ADJUVANT IMMUNOTHERAPY IN THE NIAGARA TRIAL USING GATED COUNTERFACTUAL SURVIVAL MODELING. Journal Of Urology 2026, 215: e843. DOI: 10.1097/01.ju.0001191520.88130.94.19.
- Jalfon M, Rahman S, Hesse D, Ghali F. IP41-21 EVALUATING EFFECT OF PRIOR CHECKPOINT INHIBITOR EXPOSURE ON DISEASE CONTROL WITH ENFORTUMAB VEDOTIN + PEMBROLIZUMAB IN FIRST LINE METASTATIC BLADDER CANCER. Journal Of Urology 2026, 215: e844. DOI: 10.1097/01.ju.0001191520.88130.94.21.
- Palencia P, Sivanesan N, Rahman S, Ghali F, Hesse D, Colberg J, Sridhar A, Kelly J, Lee B, Kamat A, Tan W. Partial Cystectomy for Muscle-Invasive Bladder Cancer. Cancers 2025, 17: 2562. PMID: 40805257, PMCID: PMC12346575, DOI: 10.3390/cancers17152562.
- Rahman S, Martin D, Keervani K, James S, Humphrey P, Hesse D, Tan W, Patel S, Wright J, Ghali F. Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer. Cancers 2025, 17: 2536. PMID: 40805235, PMCID: PMC12346734, DOI: 10.3390/cancers17152536.
- Smani S, Lokeshwar S, Jalfon M, Heckscher D, Press B, Heacock D, Leapman M, Kenney P, Ghali F. Development and Utilization of a Novel Electronic Health Record–Based Care Pathway for Nonmuscle-Invasive Bladder Cancer. Urology Practice 2025, 12: 628-631. PMID: 40637707, DOI: 10.1097/upj.0000000000000872.
- James S, Rahman S, Ghali F. MP14-05 MODELING SURVIVAL OUTCOMES OF KEYNOTE-564 WITH STANDARD OF CARE CONTROL ARM TREATMENT: A SIMULATION STUDY. Journal Of Urology 2025, 213: e486. DOI: 10.1097/01.ju.0001109872.73672.99.05.
- Smani S, DuBois J, Zhao K, Sutherland R, Rahman S, Humphrey P, Hesse D, Tan W, Martin D, Lokeshwar S, Ghali F. Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer. Current Oncology Reports 2025, 27: 236-246. PMID: 39976835, DOI: 10.1007/s11912-025-01645-7.
- Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.
- Bakaloudi D, Koehne E, Diamantopoulos L, Holt S, Sekar R, Ghali F, Vakar-Lopez F, Nyame Y, Psutka S, Gore J, de la Calle C, Lin D, Schade G, Liao J, Hsieh A, Yezefski T, Hawley J, Yu E, Montgomery R, Grivas P, Wright J. Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study. Clinical Genitourinary Cancer 2024, 22: 102208. PMID: 39265260, DOI: 10.1016/j.clgc.2024.102208.
- Ghali F, Holt S, Koehne E, Chen J, Weg E, Liao J, Zeng J, Grivas P, Hawley J, Hsieh A, Montgomery R, Wright J. Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older. Frontiers In Oncology 2024, 14: 1341655. PMID: 38812783, PMCID: PMC11133586, DOI: 10.3389/fonc.2024.1341655.
- Koehne E, Bakaloudi D, Ghali F, Nyame Y, Schade G, Grivas P, Yezefski T, Hawley J, Yu E, Hsieh A, Montgomery R, Psutka S, Gore J, Wright J. Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102100. PMID: 38763862, DOI: 10.1016/j.clgc.2024.102100.
- Rahman S, Ryan S, Kim J, Kenney P, Ghali F. Clinical Trials and Climate Change: Doing Our Part While Pursuing Progress. European Urology Focus 2023, 9: 861-862. PMID: 38042649, DOI: 10.1016/j.euf.2023.11.011.
- Ghali F, Vakar-Lopez F, Roudier M, Garcia J, Arora S, Cheng H, Schweizer M, Haffner M, Lee J, Yu E, Grivas P, Montgomery B, Hsieh A, Wright J, Lam H. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. Clinical Genitourinary Cancer 2023, 21: 669-678. PMID: 37344281, PMCID: PMC10674028, DOI: 10.1016/j.clgc.2023.05.014.
- Ghali F, Wright J, Grivas P. The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities. European Urology Oncology 2023, 6: 321-322. PMID: 37045706, DOI: 10.1016/j.euo.2023.03.006.
- Ghali F, Zhao Y, Patel D, Jewell T, Yu E, Grivas P, Montgomery R, Gore J, Etzioni R, Wright J. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis. European Urology Open Science 2022, 47: 58-64. PMID: 36601043, PMCID: PMC9806712, DOI: 10.1016/j.euros.2022.11.003.
- Raheem A, Landi I, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, De Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Santok G, Tadifa J, Syling J, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Bazan A, Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Ghaith A, Hagras A, Ghoneem A, Eissa A, Alqahtani A, Rumaih A, Alwahabi A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study. International Journal Of Urology 2022, 30: 308-317. PMID: 36478459, DOI: 10.1111/iju.15108.
- Miron B, Hawley J, Geynisman D, Mouw K, Sfakianos J, Weg E, Ghali F, Wright J, Grivas P, Khaki A. Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer. Advances In Oncology 2022, 2: 213-225. DOI: 10.1016/j.yao.2022.02.007.
- Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Roussel E, Pavan N, Antonelli A, Zhang S, Ghali F, Patel D, Javier-Desloges J, Bradshaw A, Rubio J, Guruli G, Tracey A, Campi R, Albersen M, Furlan M, McKay RR, Derweesh IH. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer 2022, 20: 326-333. PMID: 35585014, DOI: 10.1016/j.clgc.2022.03.013.
- Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.
- Javier-DesLoges J, Meagher M, Soliman S, Yuan J, Hakimi K, Ghali F, Nalawade V, Patel DN, Monga M, Murphy JD, Derweesh I. Disparities in Telemedicine Utilization for Urology Patients During the COVID-19 Pandemic. Urology 2022, 163: 76-80. PMID: 34979219, PMCID: PMC8719918, DOI: 10.1016/j.urology.2021.11.037.
- Javier-DesLoges JF, Meagher MF, Walia A, Nguyen MV, Perry JM, Narasimhan RS, Hakimi K, Soliman S, Yuan J, Chakoumakos MA, Ghali F, Patel DN, Wan F, Murphy JD, Derweesh IH. Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients. Urologic Oncology Seminars And Original Investigations 2021, 39: 837.e1-837.e7. PMID: 34580026, DOI: 10.1016/j.urolonc.2021.08.021.
- Ghali F, Kane C. Re: Association of Black Race with Prostate Cancer–specific and Other-cause Mortality. European Urology 2021, 80: 758-759. PMID: 34535345, DOI: 10.1016/j.eururo.2021.09.004.
- Abdel Raheem A, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, DE Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Tadifa J, Santok G, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Aguilera Bazan A, Ballesteros Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Alwahabi A, Alqahtani A, Rumaih A, Ghaith A, Ghoneem A, Hagras A, Eissa A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. Warm ischemia time length during on-clamp partial nephrectomy: dose it really matter? Minerva Urologica E Nefrologica 2021, 74: 194-202. PMID: 34308610, DOI: 10.23736/s2724-6051.21.04466-9.
- Javier-DesLoges JF, Yuan J, Soliman S, Hakimi K, Meagher MF, Ghali F, Hsiang W, Patel DN, Kim SP, Murphy JD, Parsons JK, Derweesh IH. Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act. JAMA Network Open 2021, 4: e2116267. PMID: 34269808, PMCID: PMC8285737, DOI: 10.1001/jamanetworkopen.2021.16267.
- Wu Z, Chen Q, Djaladat H, Minervini A, Uzzo R, Sundaram C, Rha K, Gonzalgo M, Mehrazin R, Mazzone E, Marcus J, Danno A, Porter J, Asghar A, Ghali F, Guruli G, Douglawi A, Cacciamani G, Ghoreifi A, Simone G, Margulis V, Ferro M, Tellini R, Mari A, Srivastava A, Steward J, Al-Qathani A, Al-Mujalhem A, Bhattu A, Mottrie A, Abdollah F, Eun D, Derweesh I, Veccia A, Autorino R, Wang L. A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group). European Urology Focus 2021, 8: 173-181. PMID: 33549537, DOI: 10.1016/j.euf.2021.01.014.
- Patel DN, Ghali F, Meagher MF, Javier-Desloges J, Patel SH, Soliman S, Hakimi K, Yuan J, Murphy J, Derweesh IH. Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database. Urologic Oncology Seminars And Original Investigations 2020, 39: 79.e1-79.e8. PMID: 33160847, DOI: 10.1016/j.urolonc.2020.10.015.
- Ghali F, Daly W, Hansen M, Hayn M, Sammon J, Beaule L, Sarkar R, Murphy J, Kader A, Derweesh I, Rose B, Ryan S. Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy. Urologic Oncology Seminars And Original Investigations 2020, 39: 130.e1-130.e7. PMID: 33121914, DOI: 10.1016/j.urolonc.2020.08.035.
- Ryan S, Patel D, Ghali F, Patel S, Sarkar R, Yim K, Eldefrawy A, Cotta B, Bradshaw A, Meagher M, Hamilton Z, Murphy J, Derweesh I. Impact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database. Minerva Urologica E Nefrologica 2020, 73: 233-244. PMID: 32748614, DOI: 10.23736/s2724-6051.20.03728-5.
- Meagher M, Lane B, Capitanio U, Mehrazin R, Bradshaw A, Noyes S, Larcher A, Eldefrawy A, Ghali F, Patel D, Bruinius J, Dutt R, Keiner C, Miller N, Wan F, Montorsi F, Derweesh I. Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma. World Journal Of Urology 2020, 39: 1195-1201. PMID: 32556559, DOI: 10.1007/s00345-020-03299-5.
- Roussel E, Campi R, Larcher A, Verbiest A, Antonelli A, Palumbo C, Derweesh I, Ghali F, Bradshaw A, Meagher M, Heck M, Amiel T, Kriegmair M, Rubio J, Musquera M, D’Anna M, Autorino R, Guruli G, Veccia A, Linares-Espinos E, Van Bruwaene S, Hevia V, Porpiglia F, Checcucci E, Minervini A, Mari A, Pavan N, Claps F, Marchioni M, Capitanio U, Beuselinck B, Mir M, Albersen M, Group O. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. European Urology Oncology 2020, 3: 523-529. PMID: 32414697, DOI: 10.1016/j.euo.2020.04.006.
- Patel S, Uzzo R, Larcher A, Peyronnet B, Lane B, Pruthi D, Reddy M, Capitanio U, Joshi S, Noyes S, Eldefrawy A, Ghali F, Meagher M, Hamilton Z, Yim K, Nasseri R, Bradshaw A, Dey S, Kirmiz S, Wan F, Liss M, Bensalah K, Montorsi F, Derweesh I. Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical Genitourinary Cancer 2020, 18: e723-e729. PMID: 32600941, DOI: 10.1016/j.clgc.2020.05.002.
- Greear G, Ghali F, Hsieh T. Semirigid penile prosthesis: technique and review of literature. Journal Of Visualized Surgery 2020, 6: 17-17. DOI: 10.21037/jovs.2019.11.07.
- Greear G, Ghali F, Hsieh T. Semirigid penile prosthesis. ASVIDE 2020, 7: 37-37. DOI: 10.21037/asvide.2020.037.
- Hamilton Z, Capitanio U, Pruthi D, Ghali F, Larcher A, Patel D, Eldefrawy A, Patel S, Cotta B, Bradshaw A, Meagher M, Miller N, Carenzi C, Wan F, Liss M, McGregor T, Montorsi F, Derweesh I. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria. Urology 2019, 138: 60-68. PMID: 31836465, DOI: 10.1016/j.urology.2019.11.036.
- Ghali F, Elbakry A, Hamilton Z, Yim K, Nasseri R, Patel S, Eldefrawy A, Ryan S, Bradshaw A, Meagher M, Bree K, Reddy M, Lee H, Derweesh I. Robotic partial nephrectomy for clinical T2a renal mass is associated with improved trifecta outcome compared to open partial nephrectomy: a single surgeon comparative analysis. World Journal Of Urology 2019, 38: 1113-1122. PMID: 31701211, DOI: 10.1007/s00345-019-02994-2.
- Roberts J, Ghali F, Aganovic L, Bechis S, Healy K, Rivera-Sanfeliz G, Autorino R, Derweesh I. Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiology. Abdominal Radiology 2019, 44: 3893-3905. PMID: 31701194, DOI: 10.1007/s00261-019-02293-9.
- Ghali F, Patel S, Derweesh I. Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma. Journal Of Oncology 2019, 2019: 7309205. PMID: 31057615, PMCID: PMC6463563, DOI: 10.1155/2019/7309205.
- Shee K, Koo K, Wu X, Ghali F, Halter R, Hyams E. A novel ex vivo trainer for robotic vesicourethral anastomosis. Journal Of Robotic Surgery 2019, 14: 21-27. PMID: 30689167, DOI: 10.1007/s11701-019-00926-1.
- Ghali F, Dagrosa L, Moses R, Ursiny M, Eisner B, Pais V. Changing incidence of factitious renal stone disease. Clinical Nephrology 2018, 90: 102-105. PMID: 29882511, DOI: 10.5414/cn109331.
- Raheem O, Ghali F, Rajasekaran M. Chapter 26 Penile Fibrogenesis Affecting Men’s Reproductive and Sexual Health Role of Age and Environmental Factors. 2018, 423-437. DOI: 10.1016/b978-0-12-801299-4.00026-8.
- Shee K, Ghali F, Hyams E. Practice Makes Perfect: Correlations Between Prior Experience in High-level Athletics and Robotic Surgical Performance Do Not Persist After Task Repetition. Journal Of Surgical Education 2017, 74: 630-637. PMID: 28087244, DOI: 10.1016/j.jsurg.2016.12.008.
- Ghali F, Celaya M, Laviolette M, Ingimarsson J, Carlos H, Rees J, Hyams E. Does Travel Time to a Radiation Facility Impact Patient Decision‐Making Regarding Treatment for Prostate Cancer? A Study of the New Hampshire State Cancer Registry. The Journal Of Rural Health 2016, 34: s84-s90. PMID: 27862285, DOI: 10.1111/jrh.12224.
- Ghali F, Moses R, Raffin E, Hyams E. What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution’s experience. Scandinavian Journal Of Urology 2016, 50: 370-373. PMID: 27438524, DOI: 10.1080/21681805.2016.1201856.
- Dagrosa L, Ghali F, Gormley E. Renal Papillary Necrosis Appearing as Bladder Cancer on Imaging. Journal Of Endourology Case Reports 2016, 2: 27-29. PMID: 27579408, PMCID: PMC4996587, DOI: 10.1089/cren.2016.0011.
- Ghali F, Pattison E, Pais V. Keratinized squamous metaplasia of the upper urinary tract resulting in recurrent renal colic. Clinical Nephrology 2015, 84: 251-3. PMID: 26249552, DOI: 10.5414/cn108581.
- Moses R, Ghali F, Pais V, Hyams E. Unplanned Hospital Return for Infection following Ureteroscopy—Can We Identify Modifiable Risk Factors? Journal Of Urology 2015, 195: 931-936. PMID: 26410731, DOI: 10.1016/j.juro.2015.09.074.
- Ghali F, Hyams E. Heterotopic Pancreatic Tail Appearing as Adrenal Mass in a Patient With Left Pelvic Kidney. Urology 2015, 85: e37-e38. PMID: 25917743, DOI: 10.1016/j.urology.2015.01.037.
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Yale Physicians Building800 Howard AvenueNew Haven, CT 06519
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- VA Connecticut Healthcare950 Campbell AvenueWest Haven, CT 06516
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Yale Physicians Building800 Howard AvenueNew Haven, CT 06519
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- VA Connecticut Healthcare950 Campbell AvenueWest Haven, CT 06516